Zanolimumab: Difference between revisions
Content deleted Content added
Updating {{drugbox}} (no changed fields - added verified revid - updated 'UNII_Ref', 'ChemSpiderID_Ref', 'StdInChI_Ref', 'StdInChIKey_Ref', 'ChEMBL_Ref') per Chem/Drugbox validation (report [[Wik |
No edit summary |
||
Line 1: | Line 1: | ||
{{drugbox |
{{drugbox |
||
| UNII_Ref = {{fdacite|correct|FDA}} |
|||
| UNII = HG3L8885M0 |
|||
| verifiedrevid = 409117208 |
| verifiedrevid = 409117208 |
||
| type = mab |
| type = mab |
Revision as of 02:24, 1 July 2011
Monoclonal antibody | |
---|---|
Type | Whole antibody |
Source | Human |
Target | CD4 |
Clinical data | |
ATC code |
|
Identifiers | |
CAS Number | |
UNII | |
KEGG | |
Chemical and physical data | |
Molar mass | 147 kDa |
(verify) |
Zanolimumab (expected trade name HuMax-CD4[1]) is a human monoclonal antibody and an immunosuppressive drug. It is being developed for the treatment of rheumatoid arthritis, psoriasis, melanoma [2], cutaneous and peripheral T-cell lymphoma.[3][4]
References
- ^ Genmab initiates Phase II Study with HuMax-CD4
- ^ http://www.tenxbiopharma.com/development.shtml
- ^ Statement On A Nonproprietary Name Adopted By The USAN Council - Zanolimumab, American Medical Association.
- ^ Clinical trial number NCT00042406 for "Trial With HuMax-CD4 in Patients With Rheumatoid Arthritis Failing Treatment With Methotrexate and a TNF-Alpha Blocker" at ClinicalTrials.gov